Can the measles‑mumps‑rubella (MMR) vaccine be given to a patient with adrenal insufficiency who is on physiologic glucocorticoid replacement?

MMR Vaccination in Adrenocortical Deficiency

Yes, MMR vaccination can and should be administered to patients with adrenal insufficiency who are on physiologic glucocorticoid replacement therapy. This is explicitly safe and not contraindicated according to established guidelines.

Key Recommendation

Physiologic maintenance doses of glucocorticoids (replacement therapy for adrenal insufficiency) do NOT contraindicate administration of live virus vaccines such as MMR. 1

Understanding the Distinction

The critical distinction here is between:

• Physiologic replacement doses (what patients with adrenal insufficiency receive) - these are SAFE for MMR vaccination
• Immunosuppressive doses (≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥14 days) - these require delaying live vaccines

What Constitutes Physiologic Replacement?

Physiologic replacement typically means:

• Hydrocortisone: 15-25 mg/day equivalent
• Prednisone: 4-6 mg/day equivalent 2

These doses are designed to replace what the body would normally produce, not to suppress the immune system.

Clinical Algorithm

For patients with adrenocortical deficiency:

1. Confirm the glucocorticoid dose is physiologic replacement (not immunosuppressive)

   • If yes → Proceed with MMR vaccination 1
   • Document that patient is on replacement therapy only

2. Verify no other contraindications exist:

   • Not severely immunocompromised from other causes 3
   • No pregnancy 3
   • No fever >101.3°F 3
   • No history of anaphylaxis to vaccine components 3

3. Administer MMR vaccine as per standard schedule

Important Caveats

Do NOT confuse adrenal insufficiency on replacement therapy with immunosuppression. The ACIP guidelines explicitly state that steroid therapy does not contraindicate MMR when it involves "physiologic maintenance doses (replacement therapy)." 1

The only glucocorticoid scenarios requiring MMR delay are:

• High-dose therapy: ≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥14 days
• In these cases, wait at least 1 month after cessation of therapy 1

Patients with underlying diseases that themselves suppress immunity (separate from their glucocorticoid use) should be evaluated individually, but isolated adrenal insufficiency does NOT suppress immunity 1

Practical Considerations

• No special monitoring required beyond standard post-vaccination observation
• No need to adjust glucocorticoid dosing around vaccination
• Standard MMR schedule applies: 2 doses for most adults at high risk, 1 dose for other adults 4
• Vaccine effectiveness remains high in patients on physiologic replacement 5

The evidence consistently supports that physiologic glucocorticoid replacement for adrenal insufficiency does not create clinically significant immunosuppression that would contraindicate live virus vaccination. This is fundamentally different from pharmacologic immunosuppressive therapy.